In early June, the House Appropriations Committee approved a FY 2027 funding measure that includes incremental increases for diabetes research and prevention programs at the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC). Almost all are increases above the fiscal year 2026 (FY26) funding level. Details of the proposal are as follows:
- Increases funding for the NIH by $100 million.
- Increases funding for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) by $22 million increase.
- Allocates $873,199,000 to the CDC’s Center for Chronic Disease Prevention and Health Promotion, which houses the Division of Diabetes Translation (DDT), the National Diabetes Prevention Program (National DPP), and the Division of Nutrition, Physical Activity, and Obesity (DNPAO).
- Increases funding for DDT by $2 million.
- Increases funding for National DPP by $2 million.
- Decreases funding for DNPAO by $37.8 million.
We remain strongly committed to advocating for diabetes research and program funding, while we are appreciative of these incremental increases for key diabetes research and prevention programs, the burden of diabetes and obesity is outpacing this investment. The American Diabetes Association® will continue to advocate for robust federal investment to address the growing burden of diabetes and preserve momentum in innovation and biomedical research. We will continue urging Congress to treat diabetes research as a national priority and increase support for essential diabetes programs across the federal government this year.
Read our full statement in our newsroom.
